Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 2,666 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 2,666 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $360.00, for a total value of $959,760.00. Following the sale, the senior vice president owned 812 shares of the company’s stock, valued at approximately $292,320. This trade represents a 76.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Thursday, July 30th, Chan Henry Lee sold 1,044 shares of BeOne Medicines stock. The shares were sold at an average price of $323.69, for a total value of $337,932.36.
• On Wednesday, July 8th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The shares were sold at an average price of $302.46, for a total transaction of $200,833.44.
• On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The stock was sold at an average price of $265.98, for a total transaction of $156,928.20.
• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The stock was sold at an average price of $257.63, for a total transaction of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total transaction of $235,535.82.

BeOne Medicines Stock Performance

ONC stock traded down $3.04 during midday trading on Thursday, reaching $356.01. 355,456 shares of the company’s stock traded hands, compared to its average volume of 423,158. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $253.95 and a 52-week high of $385.22. The stock has a market cap of $39.06 billion, a P/E ratio of 63.21 and a beta of 0.49. The stock’s 50-day moving average is $302.92 and its 200 day moving average is $309.24.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. The firm had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. As a group, analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 7.3 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ONC shares. Citigroup reaffirmed an “outperform” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Leerink Partners increased their target price on shares of BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a report on Friday, May 15th. Wolfe Research restated an “outperform” rating and set a $370.00 target price on shares of BeOne Medicines in a research note on Monday. Nomura raised shares of BeOne Medicines to a “strong-buy” rating in a report on Monday, July 27th. Finally, Zacks Research upgraded shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, BeOne Medicines has a consensus rating of “Buy” and a consensus target price of $402.14.

Key BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne Medicines reported quarterly earnings of $2.05 per share, well above the $1.40 consensus estimate, while revenue reached approximately $1.71 billion, exceeding expectations and representing roughly 30% growth. The results reinforce the company’s commercial momentum. BeOne Medicines Q2 2026 earnings call highlights
• Positive Sentiment: UBS maintained its Buy rating on BeOne Medicines, signaling continued confidence in the company’s growth outlook and oncology portfolio. UBS maintains Buy rating on BeOne Medicines
• Positive Sentiment: BeOne’s collaboration with Revolution Medicines to fund and develop the Phase 3 RAS(ON) program could expand BeOne’s targeted-cancer pipeline and create future commercialization opportunities. Revolution Medicines’ shares rose following the announcement, suggesting investors viewed the deal as strategically meaningful. Revolution Medicines rises after BeOne-funded Phase 3 RAS(ON) deal
• Negative Sentiment: CEO John Oyler sold 240,810 shares across transactions dated August 10–12 for approximately $86.5 million, substantially reducing his direct ownership. The sales may pressure sentiment, particularly with ONC trading near its 52-week high, although they were executed under a pre-arranged Rule 10b5-1 plan and therefore may not reflect a new negative view of the company. SEC filing on John Oyler’s BeOne Medicines stock sales

Hedge Funds Weigh In On BeOne Medicines

Several large investors have recently made changes to their positions in ONC. EFG International AG bought a new position in shares of BeOne Medicines in the fourth quarter worth about $25,000. Leonteq Securities AG purchased a new position in BeOne Medicines in the 4th quarter worth approximately $35,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines in the 2nd quarter worth approximately $35,000. CWM LLC boosted its stake in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares during the period. Finally, Group One Trading LLC purchased a new stake in BeOne Medicines during the 4th quarter valued at approximately $61,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.